Such studies would thus determine the potential of combining CDK4/6 inhibitors with inhibitors of adaptive metabolic pathways, such as glutaminase inhibitors, as a future therapeutic option for melanoma patients that do not respond to currently available treatments. This evidence concerns the gene CDK4 and melanoma.